|
|
Home > A review of cross-protection against oncogenic HPV
| | |
|
Blog - A review of cross-protection against oncogenic HPV
|
Last Updated Sept 2008
|
|
|
|
Human papilloma virus (HPV)-16 and -18 are responsible for approximately 70% of invasive cervical cancers worldwide. Other oncogenic HPV types account for almost all the remainder. Importantly, HPV-45 and -31 account for approximately 10%. HPV-18 and -45, along with HPV-16, are found in over 90% of endocervical adenocarcinomas. HPV-45 is the third most frequent HPV type in cervical carcinoma and adenocarcinoma. The AS04-adjuvanted vaccine Cervarix was developed against HPV-16 and -18 focusing on preventing cervical cancer by inducing durable protection against new infection. In clinical trials, it shows evidence of cross-protection against other important oncogenic HPV types using a range of clinicopathological and virological endpoints. The current evidence suggesting the cross-protective effect comes from its overall impact on precancerous lesions and on 12-month or more persistent oncogenic HPV infection, together with specific evidence of protection against incident and new persistent infection lasting 6 months or more with individual HPV types. The use of virological endpoints for such studies is discussed, in particular for cross-protection evaluation, in view of the lower frequency of many important oncogenic HPV types other than HPV-16 or -18 in precancerous lesions and the frequent presence of multiple HPV infections. Both of these factors complicate the interpretation of type-specific, vaccine-induced protection against cervical intraepithelial neoplasia (CIN) lesions, in which other HPV DNA types are found along with HPV-16 and -18. The observed high level of overall protection against clinicopathological lesions, including CIN2+ in the vaccinated subjects (regardless of their HPV DNA status), predicts a potentially broader impact of the vaccine in the prevention of HPV-related precancers that goes beyond HPV-16 and -18. The prevention of persistent infections by individual types such as HPV-45 provides specific information on the protection against that type, using an alternative endpoint that relates to both precancer and cancer development. Together with sustained protection against HPV-16 and -18, protection against HPV-45 could offer an additional effect on invasive cervical cancer and may have an important impact on endocervical adenocarcinoma, which is not effectively prevented by screening and is becoming increasingly important in young women.
|
|
Posted by D. Jenkins Sept 2008
|
| Comments 0 of 0
|
|
|
|
If you would like to comment on this post, please fill out the form below.
|
* denotes required field
Post Your Comments On*
Comment*
99999 characters remaining
|
| *All comments will undergo a review process before they are posted online. This is to prevent spam and ads from being posted. Thank you for your time and patience.
|
|
Opinions expressed on the ACC Corporation Blog and all corresponding comments are the individual opinions of the original authors and don’t in any way reflect the opinions of ACC Corporation.
|
| |
| | |
|
You must be logged in to view your shopping cart information
We accept all major credit cards
We have clients in over
75 countries spanning 5
continents
Advertise with American Custom Chemical Corporations. We make it beneficial and profitable for you to work with us.
To track your order please click on the shipping options below
For the latest updates on industry information and news
|
|